Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women

Journal of Clinical Oncology

Volumn 14, Issue 1, 1996, Pages 78-84

  Powles, T J ^a   Hickish, T ^a   Kanis, J A ^a   Tidy, A ^a   Ashley, S ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; ESTROGEN RECEPTOR; MEDROXYPROGESTERONE ACETATE; PLACEBO; TAMOXIFEN;

ADULT; ARTICLE; BONE MINERALIZATION; BREAST CARCINOMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; HIP; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; OSTEOPOROSIS; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0030070093     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.1.78     Document Type: Article

References (42)

1. Fisher B, Brown A, Wolmark N, et al: Prolonging tamoxifen therapy for primary breast cancer: Findings from the National Surgical Adjuvant Breast and Bowel Project clinical trial. Ann Intern Med 106:649-654, 1987
2. Early Breast Cancer Trialists' Collaborative Group: Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer: An overview of 61 randomised trials among 28,896 women. N Engl J Med 319:1681-1692, 1988
3. Early Breast Cancer Trialists' Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 339:1-15, 71-85, 1992
4. Cuzick J, Baum M: Tamoxifen and contralateral breast cancer. Lancet 2:282, 1985 (letter)
5. Jordan VC: Effect of tamoxifen (ICI 46, 474) on initiation and growth of DMBA-induced rat mammary carcinomata. Eur J Cancer 12:419-424, 1976
6. Gottardis MM, Jordan VC: The antitumour actions of keoxifene and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma model. Cancer Res 47:4020-4024, 1987
7. Jordan VC, Lababidi MK, Langan-Fahey S: Suppression of mouse mammary tumorigenesis long-term tamoxifen therapy. J Natl Cancer Inst 83:492-496, 1991
8. Powles TJ, Davey JB, McKinna A: A feasibility trial of tamoxifen chemoprevention of breast cancer in Great Britain. Cancer Invest 6:621-624, 1988
9. Gotfriedsen A, Christiansen C, Palshof T: The effect of tamoxifen on bone mineral content in premenopausal women with breast cancer. Cancer 53:853-857, 1984
10. Love RR, Mazess RB, Rormey DC, et al: Bone mineral density in women with breast cancer treated with adjuvant tamoxifen for at least two years. Breast Cancer Res Treat 12:297-301, 1988
11. Love RR, Mazess RB, Barden HS, et al: Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 326:852-856, 1992
12. Fornander T, Rutquist LE, Sjoberg HE, et al: Long-term adjuvant tamoxifen in early breast cancer: Effect on bone mineral density in postmenopausal women. J Clin Oncol 8:1019-1024, 1990
13. Neal AJ, Evans K, Hoskin PJ: Does long-term administration of tamoxifen affect bone mineral density? Eur J Cancer 29A:1971-1973, 1993
14. Türken S, Siris E, Seidin D: Effects of tamoxifen on spinal bone density in women with breast cancer. J Natl Cancer Inst 81:1086-1088, 1989
15. Ryan WG, Wolter J, Bagdade JD: Apparent beneficial effect of tamoxifen on bone mineral content in patients with breast cancer: A preliminary study. Osteoporosis Int 2:39-41, 1992
16. Ward RL, Morgan G, Dalley D, et al: Tamoxifen reduces bone turnover and prevents lumbar spine and proximal femoral bone loss in early postmenopausal women. Bone Miner 22:87-94, 1993
17. Kristensen B, Ejlersten B, Dalgaard P, et al: Tamoxifen and bone metabolism in postmenopausal low-risk breast cancer patients: A randomized study. J Clin Oncol 12:992-997, 1994
18. Fentiman IS, Caleffi M, Rodin A, et al: Bone mineral content of women receiving tamoxifen for mastalgia. Br J Cancer 60:262-264, 1989
19. Taube T, Elomaa I, Blomqvist C, et al: Histomorphometric evidence for osteoclast-mediated bone resorption in metastatic breast cancer. Bone 15:161-166, 1994
20. Powles TJ, Hardy JR, Ashley SE, et al: A pilot trial to evaluate the acute toxicity and feasibility of tamoxifen for prevention of breast cancer. Br J Cancer 60:126-133, 1989
21. Powles TJ, Jones AL, Ashley SE, et al: The Royal Marsden Hospital pilot tamoxifen chemoprevention trial. Breast Cancer Res Treat 31:73-82, 1994
22. Lindsay R, Hart DN, Aitken JM, et al: Long term prevention of postmenopausal osteoporosis by oestrogen: Evidence for an increase in bone mass after delayed onset of oestrogen treatment. Lancet 1:1038-1041, 1976
23. Lufkin EG, Wahner HW, O'Fallon WM, et al: Treatment of osteoporosis with transdermal oestrogen. Ann Intern Med 117:1-9, 1992
24. Kanis JA: Osteoporosis. Oxford, United Kingdom, Blackwell Science, 1994
25. Wright CDP, Mansell RE, Gazet J-C, et al: Effect of long-term tamoxifen treatment on bone turnover in women with breast cancer. Br Med J 306:429-430, 1993
26. Wright CDP, Garrahan NJ, Stanton M, et al: Effect of long-term tamoxifen therapy on cancellous bone remodelling and structure in women with breast cancer. J Bone Miner Res 9:153-159, 1994
27. Feldman S, Minne HW, Parvizi S, et al: Antioestrogen and antiandrogen administration reduce bone mass in the rat. Bone Miner 7:245-254, 1989
28. Turner RT, Wakeley GK, Hannon KS, et al: Tamoxifen prevents the skeletal effects of ovarian hormone deficiency in rats. J Bone Miner Res 2:449-456, 1987
29. Turner RT, Wakeley GK, Hannon KS, et al: Tamoxifen inhibits osteoclast-mediated resorption of trabecular bone in ovarian hormone-deficient rats. Endocrinology 122:1146-1150, 1988
30. Gallagher A, Chambers TJ, Tobias JH: The estrogen antagonist ICI 182,780 reduces cancellous bone volume in female rats. Endocrinology 133:2787-2791, 1993
31. Katzenellenbogen BS, Bhakoo HS, Ferguson BR, et al: Estrogen and antiestrogen action in reproductive tissues and tumours. Recent Prog Hormone Res 35:259-300, 1979
32. Ferguson ER, Katzenellenbogen JA: A comparative study of antiestrogen action: Temporal patterns of antagonisms of estrogen stimulate uterine growth and effects of estrogen receptor levels. Endocrinology 100:1242-1251, 1977
33. Clark JH, Anderson JN, Peck EJJ: Estrogen receptor anti-estrogen complex: Atypical binding by uterine nuclei and effects on uterine growth. Steroids 22:707-718, 1973
34. Wakeling AE, Dukes M, Bowler JA: A potent pure specific anti oestrogen with clinical potential. Cancer Res 51:3867-3873, 1991
35. Komm BS, Terpening CM, Benz DJ, et al: Estrogenic binding, receptor mRNA and biologic response in osteoblast-like osteosarcoma cells. Science 241:81-83, 1988
36. Eriksen EF, Colvard DS, Berg NJ, et al: Evidence of estrogen receptors in normal human osteoblast-like cells. Science 241:84-86, 1988
37. Ernst M, Parker MG, Rodan GA: Functional estrogen receptors in osteoblastic cells demonstrated by transfection with a reporter gene containing an estrogen response element. Mol Endocrinol 5:1597-1606, 1991
38. Migliaccio S, Davis VL, Gibson MK, et al: Estrogens modulate the responsiveness of osteoblast-like cells (ROS 17/2.8) stably transfected with estrogen receptor. Endocrinology 130:2617-2624, 1992
39. World Health Organization: Assessment of Fracture Risk in Screening for Osteoporosis. Technical Report Series no. 843. Geneva, Switzerland, WHO, 1994
40. Cundy T, Cornish J, Evans MC, et al: Recovery of bone density in women who stop using medroxyprogesterone acetate. Br Med J 308:247-248, 1994
41. Cann CE, Hanzl MR, Burrk K, et al: Reversible bone loss is produced by GnRH agonist nafarelin, in Cohn DV, Martin TJ, Meunier PJ (eds): Calcium Regulation and Bone Metabolism: Basic and Clinical Aspects. Amsterdam, the Netherlands, Elsevier, 1987, pp 123-127
42. Parfitt AM: Age related structural changes in trabecular and cortical bone: Cellular mechanisms and biomechanical consequences. Calcif Tissue Int 36:S123-128, 1984 (suppl 1)